Does CareFirst BlueCross BlueShield Cover Mounjaro?
The verdict
Conditional on most plans
CareFirst BlueCross BlueShield (serving Maryland, Washington DC, and Northern Virginia) covers Mounjaro for type 2 diabetes with prior authorization across commercial, ACA, and Medicare Part D lines. CareFirst does not cover Mounjaro for weight loss. The weight-loss tirzepatide product is Zepbound, with separate coverage. Medicaid coverage is state-dependent across CareFirst's three-jurisdiction mid-Atlantic footprint.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with CareFirst BlueCross BlueShield using your member ID.
Key facts
CareFirst BlueCross BlueShield is the mid-Atlantic Blue for Maryland, Washington DC, and Northern Virginia — each jurisdiction may have different Medicaid PDL terms for GLP-1 coverage.
CareFirst BlueCross BlueShield, Member Plan Information
Highmark is the adjacent Blue covering Pennsylvania, Delaware, West Virginia, and parts of New York; both Highmark and CareFirst follow the standard Blue T2D-with-PA pattern with state-dependent Medicaid.
BCBS Association, Licensee Map
The 2026 Medicare Part D out-of-pocket cap is $2,100. Most Mounjaro users for diabetes who stay on therapy continuously reach this cap within 2–3 months and pay $0 for the rest of the year.
CMS Medicare Part D Redesign, 2026
Medicare vs. commercial coverage
Whether CareFirst BlueCross BlueShield covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
CareFirst Medicare Advantage and Part D plans cover Mounjaro for type 2 diabetes only — not weight loss — with prior authorization. The 2026 Part D out-of-pocket cap is $2,100; most continuous Mounjaro users for diabetes reach it within 2–3 months and pay $0 for the remainder of the year. The IRA-negotiated Medicare MFN price of $245/month begins mid-2026. Mounjaro is NOT included in the 2026 Medicare GLP-1 Bridge ($50/month), which covers weight-loss-approved products only. The Lilly savings card is not usable by Medicare or Medicaid beneficiaries.
Commercial / Employer
Group & marketplace plans
CareFirst commercial and employer-sponsored plans: Mounjaro is covered for type 2 diabetes with prior authorization (A1c 6.5% or higher, metformin trial). Specific tier placement is not publicly confirmed at the drug level — verify on the CareFirst formulary for your specific plan. Not covered for off-label weight loss. ACA/Individual: diabetes only, PA; weight-loss GLP-1s commonly excluded. Medicaid: state-dependent across MD/DC/VA — verify on the applicable state or DC Medicaid PDL. Lilly savings card: $25/month with commercial coverage; $499/month without (max $647/month, up to 13 fills, expires 12/31/2026). Not available to Medicare or Medicaid beneficiaries.
The 5 boxes you must tick to get approved
Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Approximately $1,300–$1,560/month retail (WAC ~$1,080). Lilly savings card: $499/month for commercially insured without coverage (max $647/month, up to 13 fills, expires 12/31/2026). Not available to Medicare or Medicaid beneficiaries.
List price with no coverage — before any manufacturer savings card.
With coverage
CareFirst plan-specific brand cost-share; tier not publicly confirmed at the drug level — verify on the CareFirst drug lookup. Commercially insured with Mounjaro coverage may pay as little as $25/month via the Lilly savings card. Medicare Part D: 25% coinsurance to the $2,100 OOP cap 2026; MFN $245/month mid-2026. Medicaid: state-dependent nominal copay across MD/DC/VA.
Typical monthly copay once prior authorization is approved.
Bridge program
The 2026 Medicare GLP-1 Bridge ($50/month) covers weight-loss-approved products only; Mounjaro is not included.
Reduced copay through the assistance program, where eligible.
All figures are estimates; confirm cost-share on the CareFirst drug lookup tool. The Lilly savings card expires 12/31/2026 and is not available to Medicare, Medicaid, or government-program beneficiaries.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Verify Mounjaro coverage on the CareFirst drug formulary
Visit carefirst.com and use the drug lookup for your specific plan (Maryland, DC, or Northern Virginia). Confirm that PA is required, look up the current tier and cost-share, and verify the PA criteria. CareFirst serves three jurisdictions — plan terms may vary between Maryland, DC, and Virginia enrollees.
- 2
Have your prescriber submit a complete prior authorization
Your prescriber must document your T2D diagnosis (ICD-10 E11.x), A1c of 6.5% or greater within ~90 days, and prior metformin trial (plus one additional agent where required). Submit through the CareFirst PA portal; allow up to 72 hours for a decision.
- 3
If you want tirzepatide for weight loss, ask about Zepbound — not Mounjaro
If your goal is weight loss rather than diabetes management, Mounjaro is the wrong product. The weight-loss tirzepatide is Zepbound, FDA-approved for chronic weight management and OSA. Ask your prescriber and CareFirst specifically about Zepbound coverage — it is a separate drug with its own, more restricted, coverage pathway.
Options if CareFirst BlueCross BlueShield won't cover Mounjaro
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide)
FDA-approved for type 2 diabetes. May be on a preferred tier ahead of Mounjaro as step therapy on CareFirst formularies.
Trulicity (dulaglutide)
FDA-approved for T2D. GLP-1 alternative; often used as a step-therapy agent before Mounjaro approval.
Jardiance (empagliflozin)
SGLT2 inhibitor for T2D with cardiovascular benefits. May be required step therapy before GLP-1 approval on CareFirst plans.
Zepbound (tirzepatide) — weight loss only
Same molecule as Mounjaro (tirzepatide) but FDA-approved for chronic weight management and OSA. Separate coverage track from Mounjaro — not a substitute for diabetes coverage.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
No. CareFirst does not cover Mounjaro for weight loss under any line of business. Mounjaro is FDA-approved for type 2 diabetes only; the PA is gated on a T2D diagnosis — off-label weight-loss requests are denied. For weight loss, the same active ingredient (tirzepatide) is Zepbound, which has a separate FDA approval for chronic weight management and OSA and its own, more restricted, coverage pathway.
CareFirst BlueCross BlueShield serves Maryland, Washington DC, and Northern Virginia. Each jurisdiction may have its own Medicaid rules and cost-share terms — verify on the CareFirst drug lookup for your specific plan location. Highmark is the adjacent Blue covering Pennsylvania, Delaware, West Virginia, and parts of New York, following a similar standard Blue T2D-with-PA pattern.
Medicaid coverage for Mounjaro is state-dependent across CareFirst's three-jurisdiction footprint. All three jurisdictions cover Mounjaro for type 2 diabetes with prior authorization per their state and DC PDLs. Weight-loss GLP-1 coverage varies by jurisdiction — verify on your specific Medicaid plan or CareFirst member services. The Lilly savings card is not available to Medicaid beneficiaries.
No. The 2026 Medicare GLP-1 Bridge ($50/month, July 1 – December 31, 2027) covers weight-loss-approved products only — Wegovy, Foundayo, and the Zepbound KwikPen. Mounjaro is excluded because it is FDA-approved for type 2 diabetes, not weight loss. CareFirst Medicare Advantage and Part D plans cover Mounjaro for T2D under standard Part D rules with PA and the $2,100 annual OOP cap in 2026.
Related Articles
Does CareFirst BlueCross BlueShield Cover Prolia? 2026 | Curex
CareFirst BCBS (MD/DC/N.VA) covers Prolia under the medical benefit with PA. Jubbonti preferred at several BCBS licensees now. Verify at carefirst.com.
Read moreDoes Blue Cross Blue Shield of Michigan Cover Mounjaro? | Curex
BCBS of Michigan covers Mounjaro for type 2 diabetes with PA, not weight loss. Zepbound weight-loss exclusion upheld by MI DIFS in 2025.
Read moreDoes Blue Cross Blue Shield of Minnesota Cover Mounjaro? 2026 | Curex
BCBS of Minnesota covers Mounjaro for type 2 diabetes with PA — not weight loss. MN Medicaid covers weight-loss GLP-1s for Zepbound, not Mounjaro.
Read moreDoes CareFirst BCBS Cover Wegovy? 2026 Guide | Curex
CareFirst BCBS covers Wegovy on large-group plans (Tier 2/4, PA required) but excludes it on ACA Exchange plans. 2026 criteria explained.
Read moreDoes CareFirst BlueCross BlueShield Cover Ozempic? 2026 | Curex
CareFirst covers Ozempic for type 2 diabetes with prior auth — not weight loss. FEHB T2D enrollees may use the NovoCare $25 card. Verify on plan lookup.
Read moreDoes Blue Cross Blue Shield of Texas Cover Mounjaro? 2026 | Curex
BCBS of Texas covers Mounjaro for type 2 diabetes with prior auth — not weight loss. The weight-loss tirzepatide is Zepbound, covered separately.
Read moreInsurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance
CareFirst covers Mounjaro for diabetes only, not weight loss — the weight-loss twin Zepbound is a separate, often-excluded question. For patients who want tirzepatide access without insurance, compounded tirzepatide from $149/mo (and compounded semaglutide from $49/mo) is available at getcurex.com/cl/glp — no insurance required, no prior authorization. This is compounded tirzepatide and is not the same medication as Mounjaro or Zepbound. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with CareFirst BlueCross BlueShield before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.